What Verdica's 799 score means for ZHEJIANG NOVUS PHARM
ZHEJIANG NOVUS PHARM's composite score of 799 out of 850 places it in the "strong" performance band (740–799), indicating a pharmacy provider with solid regulatory standing and operational compliance. A score in this range suggests that the entity has demonstrated consistent adherence to state pharmacy board requirements, FDA manufacturing standards, and DEA controlled-substance protocols, with only minor gaps or areas for improvement.
Readers should interpret this score as a positive indicator for basic regulatory fitness. The provider is not flagged as high-risk or problematic by the regulators whose records Verdica indexed. However, the score is not in the "excellent" band (800–850), meaning there are documented areas—reflected in the sub-scores—where the provider's compliance record or operational profile is not perfect. For business owners or procurement teams evaluating pharmacy suppliers, this score suggests that ZHEJIANG NOVUS PHARM meets baseline requirements and merits further due diligence but does not represent an outlier in either direction.
How the sub-scores break down
Product Approval (850/850): This sub-score reflects the regulatory status of medications and pharmaceutical products that ZHEJIANG NOVUS PHARM manufactures or distributes. A perfect score of 850 indicates that all indexed products have cleared required approval pathways—typically FDA new drug applications (NDAs), abbreviated new drug applications (ANDAs), or equivalent international registrations. In the pharmacy industry, this dimension is binary in nature: products are either approved or they are not. A maximum score here signals no record of unapproved or recalled products tied to this entity within the indexed data.
Manufacturer Profile (720/850): This sub-score is the lowest of the three and reflects the entity's operational and facility compliance history. Manufacturer profile ratings typically incorporate data on facility inspections, Good Manufacturing Practice (GMP) compliance, quality control documentation, and licensing status from state boards of pharmacy and the FDA. A score of 720 indicates that ZHEJIANG NOVUS PHARM meets required standards but has some documented observations, minor violations, or compliance gaps on record. This is not uncommon for active manufacturers and does not necessarily signal systemic problems, but it does suggest the provider is not operating at peak compliance in this category.
FDA Compliance (830/850): This sub-score reflects adherence to federal drug manufacturing, labeling, and distribution regulations. An FDA compliance score of 830 is solid, indicating no major warning letters, consent decrees, or significant enforcement actions indexed against this entity. Minor compliance notes—such as procedural clarifications requested during inspection or routine documentation issues—can account for the gap between 830 and a perfect 850, but do not suggest material regulatory concern.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records and track disciplinary actions, operational violations, and complaint resolutions. They monitor pharmacy and manufacturer compliance with state-specific regulations governing storage, handling, record-keeping, and personnel qualifications.
The FDA oversees drug manufacturing quality and safety through facility inspections, testing protocols, and post-market surveillance. FDA compliance scoring typically reflects inspection findings, warning letters, and product recall involvement.
The DEA tracks controlled-substance distribution, inventory reconciliation, and suspicious order reporting. Pharmacy providers handling Schedule II–V substances must maintain detailed records and report diversion risks.
Verdica's composite score aggregates these three regulatory streams. Providers with infractions—such as incomplete records, failed quality audits, licensing suspensions, or unresolved recall events—see corresponding sub-score reductions. Conversely, clean inspection histories and timely corrective actions support higher scores.
Bottom line
ZHEJIANG NOVUS PHARM scores in the strong compliance band, with perfect product approval standing and solid FDA performance offset by a mid-range manufacturer profile rating. Anyone considering this provider should verify current licensing status with relevant state boards, request recent FDA inspection summaries, and confirm product-specific approvals align with their procurement needs before commitment.